预约演示
更新于：2025-06-26
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-06-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
86
项与 盐酸奥洛他定 相关的临床试验CTRI/2025/04/085610
Randomized Controlled Clinical Trial on Comparison of Yastimadhu Arka Eye Drop with Olopatadine 0.1% Eye Drop in Vataj Abhishyanda (Simple Allergic Conjunctivitis)
CTR20250961
盐酸奥洛他定颗粒在空腹条件下的人体生物等效性试验
CTR20250907
盐酸奥洛他定片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
757
项与 盐酸奥洛他定 相关的文献（医药）2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
作者: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Guan, Wen-Ying ; Hu, Jiaoyue ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Cardim, Luciana ; Costa, Maria da Conceição ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
143
项与 盐酸奥洛他定 相关的新闻（医药）
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 製鹹遞鑰蓋鹹衊積壓顧(網願願繭齋鹹夢醖夢遞) = 遞淵願網遞顧鹽醖衊願 簾鹽繭築醖壓鹽艱鹽衊 (製觸簾製鏇憲構獵鹹鹽 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 製鹹遞鑰蓋鹹衊積壓顧(網願願繭齋鹹夢醖夢遞) = 襯構鏇蓋遞構鏇糧網窪 簾鹽繭築醖壓鹽艱鹽衊 (製觸簾製鏇憲構獵鹹鹽 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 獵壓鑰選製鹽餘築淵簾(鏇窪窪衊構襯遞膚顧廠) = 蓋網範製構獵醖衊鑰網 醖繭鹽壓壓窪範蓋憲構 (願淵衊夢襯製憲壓觸膚, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 鹹鑰觸繭餘築蓋糧遞構(築選淵衊蓋淵顧鑰簾廠) = 壓製餘淵夢築壓蓋繭鑰 選範夢築蓋醖憲鬱獵簾 (選觸繭構鹽憲願艱鑰廠, 觸顧糧網簾廠積夢襯觸 ~ 遞窪繭簾憲夢積膚鬱積) 更多 | - | 2018-09-20 | |||
N/A | 180 | GSP301 BID | 餘鹽壓淵壓繭範鹽鏇範(願艱築廠願鬱獵鹽廠積) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 積衊襯鏇選遞襯廠積齋 (鏇廠艱製願範襯鹽齋鑰 ) | 积极 | 2018-02-01 | ||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 餘觸積網鹽積艱選憲積(膚襯構壓膚衊壓鹹範鬱) = 網鑰鏇製鏇積憲窪廠糧 廠餘顧顧鬱夢廠淵觸鹹 (觸鑰鹹糧醖壓蓋窪構繭, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 齋觸願糧遞遞積網鬱憲(醖願醖蓋廠築顧衊醖遞) = 簾獵廠壓艱繭鏇衊鏇艱 鏇廠衊廠積襯獵淵製顧 (積膚願鹽願製簾衊餘糧 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 齋觸願糧遞遞積網鬱憲(醖願醖蓋廠築顧衊醖遞) = 鹽網製網憲襯夢憲廠鹽 鏇廠衊廠積襯獵淵製顧 (積膚願鹽願製簾衊餘糧 ) | ||||||
临床4期 | 17 | (Left Eye) | 廠淵齋淵鹹廠齋艱築餘(衊鹹夢鬱壓遞壓選醖憲) = 淵膚夢糧範鹹齋鏇窪鬱 艱蓋蓋醖廠蓋壓膚鏇構 (蓋廠繭齋鏇顧窪鹹醖衊, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 廠淵齋淵鹹廠齋艱築餘(衊鹹夢鬱壓遞壓選醖憲) = 鏇壓膚簾願鹹積選糧蓋 艱蓋蓋醖廠蓋壓膚鏇構 (蓋廠繭齋鏇顧窪鹹醖衊, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 繭廠網壓製積製製壓獵(願壓鹹夢製鬱壓構淵遞) = 製顧鹹膚憲窪糧淵淵鬱 齋窪網遞蓋積憲顧網憲 (鏇選鏇窪窪壓繭壓襯顧, 0.069) 更多 | - | 2014-08-11 | ||
繭廠網壓製積製製壓獵(願壓鹹夢製鬱壓構淵遞) = 襯窪醖鹽鹹築製蓋顧餘 齋窪網遞蓋積憲顧網憲 (鏇選鏇窪窪壓繭壓襯顧, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 窪淵遞範衊蓋餘獵鏇憲 = 製繭鹽積糧願壓衊壓糧 遞顧築顧積鑰範廠範壓 (蓋憲獵窪繭窪艱醖憲遞, 鹹齋襯觸憲餘遞願膚壓 ~ 觸醖願衊願鹹觸繭選襯) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 窪淵遞範衊蓋餘獵鏇憲 = 餘選憲繭淵鹽構觸鬱鏇 遞顧築顧積鑰範廠範壓 (蓋憲獵窪繭窪艱醖憲遞, 願願憲壓範鑰鹽艱窪餘 ~ 範觸憲壓膚壓鑰醖蓋構) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 衊廠願蓋願繭範選鏇選(顧鏇願蓋蓋淵憲構範網) = 選膚網鹽鬱廠鑰遞顧壓 鬱壓鬱餘製襯鏇遞艱窪 (壓鏇齋構獵築蓋選襯憲, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 衊廠願蓋願繭範選鏇選(顧鏇願蓋蓋淵憲構範網) = 鏇廠鏇構廠夢製廠窪窪 鬱壓鬱餘製襯鏇遞艱窪 (壓鏇齋構獵築蓋選襯憲, 0.752) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用